Actively Recruiting
Randomized Trial to Assess Safety and Effectiveness of HRS-4729 and HRS9531 Injections in Adults With Metabolic Dysfunction-Associated Steatohepatitis
Led by Fujian Shengdi Pharmaceutical Co., Ltd. · Updated on 2026-08-26
160
Participants Needed
2
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of two investigational injections, HRS-4729 and HRS9531, in adults diagnosed with metabolic dysfunction-associated steatohepatitis MASH. This phase 2 clinical trial aims to evaluate the safety and effectiveness of these treatments over a 52-week period. The study is randomized, double-blind, and placebo-controlled to ensure reliable results. Participants will be assigned to one of four groups receiving either high or low doses of HRS-4729 injection, HRS9531 injection, or matching placebos. The injections are given during the treatment period, which lasts for 52 weeks. The study also includes monitoring for any treatment-related side effects up to week 56. During the trial, participants will undergo assessments including liver fat content measurements by MRI at baseline, week 32, and week 52. Liver biopsies will be used to evaluate changes in liver histology related to MASH and fibrosis at baseline and week 52. Safety will be monitored by recording adverse events throughout the study. Participants are involved in regular evaluations to track treatment effects and safety over the year-long study.
CONDITIONS
Brief Title
A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis
Research Team
M
Mengshan Ni
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here